BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duffy MJ, Crown J. Companion biomarkers: paving the pathway to personalized treatment for cancer. Clin Chem 2013;59:1447-56. [PMID: 23656699 DOI: 10.1373/clinchem.2012.200477] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087. [PMID: 30923679 DOI: 10.1016/j.bdq.2019.100087] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 47.3] [Reference Citation Analysis]
2 Werner HMJ, Salvesen HB. Current Status of Molecular Biomarkers in Endometrial Cancer. Curr Oncol Rep 2014;16. [DOI: 10.1007/s11912-014-0403-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
3 Rebollo J, Sureda M, Martinez EM, Fernández-Morejón FJ, Farré J, Muñoz V, Fernández-Latorre F, Manzano RG, Brugarolas A. Gene Expression Profiling of Tumors From Heavily Pretreated Patients With Metastatic Cancer for the Selection of Therapy: A Pilot Study. Am J Clin Oncol 2017;40:140-5. [PMID: 25144266 DOI: 10.1097/COC.0000000000000116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
4 Liu J, Zhang W, Gu M, Ji Y, Yang L, Cheng X, Xiao X, Xu J, Gu C, Zhang J, Zhang S, Chen D, Pan S. Serum SP70 is a sensitive predictor of chemotherapy response in patients with advanced nonsmall cell lung cancer. Cancer Med 2018. [PMID: 29767438 DOI: 10.1002/cam4.1555] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
5 Dobosz M, Haupt U, Scheuer W. Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule. MAbs 2017;9:140-53. [PMID: 27661454 DOI: 10.1080/19420862.2016.1238996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Duffy MJ, Crown J. Precision treatment for cancer: Role of prognostic and predictive markers. Critical Reviews in Clinical Laboratory Sciences 2013;51:30-45. [DOI: 10.3109/10408363.2013.865700] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
7 Garrett CT. Molecular Biology Basics in the “Omics” Era: Genes to Proteins. In: Idowu MO, Dumur CI, Garrett CT, editors. Molecular Oncology Testing for Solid Tumors. Cham: Springer International Publishing; 2015. pp. 3-65. [DOI: 10.1007/978-3-319-16304-8_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Duffy MJ, O'donovan N, Mcdermott E, Crown J. Validated biomarkers: The key to precision treatment in patients with breast cancer. The Breast 2016;29:192-201. [DOI: 10.1016/j.breast.2016.07.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
9 Beard K, Meaney DF, Issadore D. Clinical Applications of Extracellular Vesicles in the Diagnosis and Treatment of Traumatic Brain Injury. J Neurotrauma 2020;37:2045-56. [PMID: 32312151 DOI: 10.1089/neu.2020.6990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sun S, Ding Z, Yang X, Zhao X, Zhao M, Gao L, Chen Q, Xie S, Liu A, Yin S, Xu Z, Lu X. Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy. Int J Nanomedicine 2021;16:2337-56. [PMID: 33790553 DOI: 10.2147/IJN.S297631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Tonge DP, Pearson MJ, Jones SW. The hallmarks of osteoarthritis and the potential to develop personalised disease-modifying pharmacological therapeutics. Osteoarthritis Cartilage 2014;22:609-21. [PMID: 24632293 DOI: 10.1016/j.joca.2014.03.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 11.4] [Reference Citation Analysis]
12 Whale AS, Jones GM, Pavšič J, Dreo T, Redshaw N, Akyürek S, Akgöz M, Divieto C, Sassi MP, He HJ, Cole KD, Bae YK, Park SR, Deprez L, Corbisier P, Garrigou S, Taly V, Larios R, Cowen S, O'Sullivan DM, Bushell CA, Goenaga-Infante H, Foy CA, Woolford AJ, Parkes H, Huggett JF, Devonshire AS. Assessment of Digital PCR as a Primary Reference Measurement Procedure to Support Advances in Precision Medicine. Clin Chem 2018;64:1296-307. [PMID: 29903874 DOI: 10.1373/clinchem.2017.285478] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
13 Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang J, Xiao N, Greil R, Rinnerthaler G, Gampenrieder SP, Heimberger AB, Berry DA, Barker A, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Magee D, Miglarese MR, Famulok M, Mayer G, Spetzler D. Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nat Commun 2018;9:1219. [PMID: 29572535 DOI: 10.1038/s41467-018-03631-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
14 Morin TJ, Shropshire T, Liu X, Briggs K, Huynh C, Tabard-Cossa V, Wang H, Dunbar WB. Nanopore-Based Target Sequence Detection. PLoS One 2016;11:e0154426. [PMID: 27149679 DOI: 10.1371/journal.pone.0154426] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
15 Andersen RF. Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to substitute mutational analyses. Expert Review of Molecular Diagnostics 2018;18:1011-9. [DOI: 10.1080/14737159.2018.1545576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Lee J, Lee J, Sim W, Kim JH. Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 Expression. Cancers (Basel) 2020;12:E277. [PMID: 31979216 DOI: 10.3390/cancers12020277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Nielsen T, Wallden B, Schaper C, Ferree S, Liu S, Gao D, Barry G, Dowidar N, Maysuria M, Storhoff J. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2014;14:177. [PMID: 24625003 DOI: 10.1186/1471-2407-14-177] [Cited by in Crossref: 186] [Cited by in F6Publishing: 151] [Article Influence: 23.3] [Reference Citation Analysis]
18 Arias-Pinilla GA, Modjtahedi H. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers (Basel) 2021;13:1781. [PMID: 33917882 DOI: 10.3390/cancers13081781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Zárate R, Lozano MD, Zubiri L, Perez-Gracia JL, Martín-Algarra S, González A. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem 2015;61:297-304. [PMID: 25411185 DOI: 10.1373/clinchem.2014.230235] [Cited by in Crossref: 178] [Cited by in F6Publishing: 170] [Article Influence: 22.3] [Reference Citation Analysis]
20 Settleman J. Predicting response to HER2 kinase inhibition. Oncotarget 2015;6:588-9. [PMID: 25655645 DOI: 10.18632/oncotarget.3036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Smith NR, Womack C. A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery. J Pathol 2014;232:190-8. [PMID: 24030847 DOI: 10.1002/path.4262] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
22 Sanmamed MF, Fernández-landázuri S, Rodríguez C, Lozano MD, Echeveste JI, Pérez Gracia JL, Alegre E, Carranza O, Zubiri L, Martín-algarra S, González A. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clinica Chimica Acta 2014;429:168-74. [DOI: 10.1016/j.cca.2013.11.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
23 Guzman NA, Guzman DE. An emerging micro-scale immuno-analytical diagnostic tool to see the unseen. Holding promise for precision medicine and P4 medicine. Journal of Chromatography B 2016;1021:14-29. [DOI: 10.1016/j.jchromb.2015.11.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
24 Holdenrieder S. Liquid Profiling of Circulating Nucleic Acids as a Novel Tool for the Management of Cancer Patients. In: Gahan PB, Fleischhacker M, Schmidt B, editors. Circulating Nucleic Acids in Serum and Plasma – CNAPS IX. Cham: Springer International Publishing; 2016. pp. 53-60. [DOI: 10.1007/978-3-319-42044-8_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Choi YJ, Kim MS, An CH, Yoo NJ, Lee SH. Regional bias of intratumoral genetic heterogeneity of nucleotide repeats in colon cancers with microsatellite instability. Pathol Oncol Res 2014;20:965-71. [PMID: 24748498 DOI: 10.1007/s12253-014-9781-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
26 Chandran V, Rahman P. Predicting therapeutic response through biomarker analysis in psoriatic arthritis, an example of precision medicine. Expert Review of Precision Medicine and Drug Development 2020;5:35-42. [DOI: 10.1080/23808993.2020.1724509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Monsma DJ, Cherba DM, Richardson PJ, Vance S, Rangarajan S, Dylewski D, Eugster E, Scott SB, Beuschel NL, Davidson PJ, Axtell R, Mitchell D, Lester EP, Junewick JJ, Webb CP, Monks NR. Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance. Pediatr Blood Cancer 2014;61:1570-7. [PMID: 24687871 DOI: 10.1002/pbc.25039] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
28 Martinez-Cardús A, Vizoso M, Moran S, Manzano JL. Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance. Ann Transl Med 2015;3:209. [PMID: 26488005 DOI: 10.3978/j.issn.2305-5839.2015.06.20] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
29 Gaule PB, Crown J, O'Donovan N, Duffy MJ. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? Expert Opin Ther Targets 2014;18:999-1009. [PMID: 25084805 DOI: 10.1517/14728222.2014.938050] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]